• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝内胆管癌的分子异质性

Molecular heterogeneity in intrahepatic cholangiocarcinoma.

作者信息

Ahn Keun Soo, Kang Koo Jeong

机构信息

Department of Surgery, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu 42601, South Korea.

出版信息

World J Hepatol. 2020 Dec 27;12(12):1148-1157. doi: 10.4254/wjh.v12.i12.1148.

DOI:10.4254/wjh.v12.i12.1148
PMID:33442444
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7772740/
Abstract

Intrahepatic cholangiocarcinoma (iCCA) is a heterogeneous primary liver cancer, and currently there exist only a few options of targeted therapy. Histopathologically, iCCA is sub-classified according to morphology (mass forming type, periductal infiltrating type, and intraductal growing type) and histology (small duct type and large duct type). According to different histopathological types, clinical features such as risk factors and prognosis vary. Recent developments in genomic profiling have revealed several molecular markers for poor prognosis and activation of oncogenic pathways. Exploration of molecular characteristics of iCCA in each patient is a major challenge in a clinical setting, and there is no effective molecular-based targeted therapy. However, several recent studies suggested molecular-based subtypes with corresponding clinical and pathological features. Even though the subtypes have not yet been validated, it is possible that molecular features can be predicted based on clinicopathological characteristics and that this could be used for a more rational approach to integrative clinical and molecular subclassification and targeted therapy. In this review, we explored the genomic landscape of iCCA and attempted to find relevance between clinicopathologic and molecular features in molecular subtypes in several published studies. The results reveal future directions that may lead to a rational approach to the targeted therapy.

摘要

肝内胆管癌(iCCA)是一种异质性原发性肝癌,目前靶向治疗选择有限。在组织病理学上,iCCA根据形态学(肿块形成型、导管周围浸润型和导管内生长型)和组织学(小导管型和大导管型)进行亚分类。根据不同的组织病理学类型,危险因素和预后等临床特征各不相同。基因组分析的最新进展揭示了几种预后不良和致癌途径激活的分子标志物。在临床环境中,探索每位iCCA患者的分子特征是一项重大挑战,并且尚无有效的基于分子的靶向治疗方法。然而,最近的几项研究提出了具有相应临床和病理特征的分子亚型。尽管这些亚型尚未得到验证,但基于临床病理特征预测分子特征并将其用于更合理的综合临床和分子亚分类及靶向治疗方法是有可能的。在本综述中,我们探讨了iCCA的基因组格局,并试图在几项已发表的研究中找出分子亚型的临床病理特征与分子特征之间的相关性。结果揭示了可能通向合理靶向治疗方法的未来方向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/affb/7772740/997d8ab50f58/WJH-12-1148-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/affb/7772740/997d8ab50f58/WJH-12-1148-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/affb/7772740/997d8ab50f58/WJH-12-1148-g001.jpg

相似文献

1
Molecular heterogeneity in intrahepatic cholangiocarcinoma.肝内胆管癌的分子异质性
World J Hepatol. 2020 Dec 27;12(12):1148-1157. doi: 10.4254/wjh.v12.i12.1148.
2
Surgical interpretation of the WHO subclassification of intrahepatic cholangiocarcinoma: a narrative review.世界卫生组织肝内胆管癌亚型分类的外科解读:一篇综述
Surg Today. 2025 Jan;55(1):1-9. doi: 10.1007/s00595-024-02825-x. Epub 2024 Apr 2.
3
Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma.肝内胆管癌的最新病理分类及分子特征
Front Med (Lausanne). 2022 Mar 31;9:857140. doi: 10.3389/fmed.2022.857140. eCollection 2022.
4
A proposal of imaging classification of intrahepatic mass-forming cholangiocarcinoma into ductal and parenchymal types: clinicopathologic significance.肝内肿块型胆管细胞癌的影像学分类提案:导管型和实质型——临床病理意义。
Eur Radiol. 2019 Jun;29(6):3111-3121. doi: 10.1007/s00330-018-5898-9. Epub 2018 Dec 17.
5
Recent Advances in Pathology of Intrahepatic Cholangiocarcinoma.肝内胆管癌病理学的最新进展
Cancers (Basel). 2024 Apr 17;16(8):1537. doi: 10.3390/cancers16081537.
6
Integrative Analysis of Intrahepatic Cholangiocarcinoma Subtypes for Improved Patient Stratification: Clinical, Pathological, and Radiological Considerations.肝内胆管癌亚型的综合分析以改善患者分层:临床、病理和影像学考量
Cancers (Basel). 2022 Jun 28;14(13):3156. doi: 10.3390/cancers14133156.
7
Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets.肝内胆管癌的分子图谱:寻找新的治疗靶点。
Expert Rev Gastroenterol Hepatol. 2017 Apr;11(4):349-356. doi: 10.1080/17474124.2017.1292127. Epub 2017 Feb 13.
8
Transcriptomic and histopathological analysis of cholangiolocellular differentiation trait in intrahepatic cholangiocarcinoma.肝内胆管癌中胆小管细胞分化特征的转录组学和组织病理学分析。
Liver Int. 2018 Jan;38(1):113-124. doi: 10.1111/liv.13492. Epub 2017 Jul 10.
9
Macroscopic types of intrahepatic cholangiocarcinoma: clinicopathologic features and surgical outcomes.肝内胆管癌的大体类型:临床病理特征及手术结果
Hepatogastroenterology. 2002 Mar-Apr;49(44):326-9.
10
Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma.肝内胆管癌的分子发病机制和靶向治疗。
Clin Cancer Res. 2016 Jan 15;22(2):291-300. doi: 10.1158/1078-0432.CCR-14-3296. Epub 2015 Sep 24.

引用本文的文献

1
Multi-Omics Classification of Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis.肝内胆管癌的多组学分类:系统评价与Meta分析
Cancers (Basel). 2024 Jul 20;16(14):2596. doi: 10.3390/cancers16142596.
2
Surgical interpretation of the WHO subclassification of intrahepatic cholangiocarcinoma: a narrative review.世界卫生组织肝内胆管癌亚型分类的外科解读:一篇综述
Surg Today. 2025 Jan;55(1):1-9. doi: 10.1007/s00595-024-02825-x. Epub 2024 Apr 2.
3
Differentially expressed non-coding RNAs and their regulatory networks in liver cancer.

本文引用的文献

1
Molecular classification of cholangiocarcinoma.胆管癌的分子分类。
Curr Opin Gastroenterol. 2020 Mar;36(2):57-62. doi: 10.1097/MOG.0000000000000611.
2
FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma.FGFR2 基因异常:晚期胆管癌治疗的阿喀琉斯之踵。
Cancer Treat Rev. 2019 Aug;78:1-7. doi: 10.1016/j.ctrv.2019.06.003. Epub 2019 Jun 22.
3
Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular-clinical analysis and potential targeted approach.基于整合分子-临床分析的肝内胆管癌预后亚类及潜在的靶向治疗方法。
肝癌中差异表达的非编码RNA及其调控网络
Heliyon. 2023 Aug 19;9(9):e19223. doi: 10.1016/j.heliyon.2023.e19223. eCollection 2023 Sep.
4
Austrian tricentric real-life analysis of molecular profiles of metastatic biliary tract cancer patients.奥地利对转移性胆管癌患者分子特征的三中心真实世界分析。
Front Oncol. 2023 May 10;13:1143825. doi: 10.3389/fonc.2023.1143825. eCollection 2023.
5
Immunotherapy and Targeted Therapy for Advanced Biliary Tract Cancer: Adding New Flavors to the Pizza.晚期胆管癌的免疫治疗和靶向治疗:为披萨增添新口味。
Cancers (Basel). 2023 Mar 25;15(7):1970. doi: 10.3390/cancers15071970.
6
Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study.石棉暴露作为小胆管型肝内胆管细胞癌的附加风险因素:一项初步研究。
Sci Rep. 2023 Feb 13;13(1):2580. doi: 10.1038/s41598-023-27791-1.
7
Lnc-PKD2-2-3/miR-328/GPAM ceRNA Network Induces Cholangiocarcinoma Proliferation, Invasion and 5-FU Chemoresistance.长链非编码RNA-PKD2-2-3/miR-328/GPAM竞争性内源RNA网络诱导胆管癌增殖、侵袭及5-氟尿嘧啶化疗耐药
Front Oncol. 2022 Jul 29;12:871281. doi: 10.3389/fonc.2022.871281. eCollection 2022.
8
Investigating VEGF. miR-145-3p, and miR-101-3p Expression in Patients with Cholangiocarcinoma.研究胆管癌患者中 VEGF、miR-145-3p 和 miR-101-3p 的表达。
Asian Pac J Cancer Prev. 2022 Jul 1;23(7):2233-2241. doi: 10.31557/APJCP.2022.23.7.2233.
9
Biliary Tract Cancers: Treatment Updates and Future Directions in the Era of Precision Medicine and Immuno-Oncology.胆道癌:精准医学与免疫肿瘤学时代的治疗进展与未来方向
Front Oncol. 2021 Nov 15;11:768009. doi: 10.3389/fonc.2021.768009. eCollection 2021.
10
Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice?肝胆癌中的生物标志物:在临床实践中有哪些有用的?
Cancers (Basel). 2021 May 30;13(11):2708. doi: 10.3390/cancers13112708.
Hepatol Int. 2019 Jul;13(4):490-500. doi: 10.1007/s12072-019-09954-3. Epub 2019 Jun 18.
4
Expression of long non-coding RNA ANRIL predicts a poor prognosis in intrahepatic cholangiocarcinoma.长链非编码 RNA ANRIL 的表达预测肝内胆管癌的预后不良。
Dig Liver Dis. 2019 Sep;51(9):1337-1343. doi: 10.1016/j.dld.2019.03.019. Epub 2019 Apr 27.
5
Functions and roles of long noncoding RNA in cholangiocarcinoma.长链非编码 RNA 在胆管癌中的功能和作用。
J Cell Physiol. 2019 Aug;234(10):17113-17126. doi: 10.1002/jcp.28470. Epub 2019 Mar 19.
6
Noncoding RNA in Cholangiocarcinoma.胆管癌中的非编码 RNA。
Semin Liver Dis. 2019 Feb;39(1):13-25. doi: 10.1055/s-0038-1676097. Epub 2018 Dec 7.
7
Cholangiocarcinoma.胆管癌
Surg Pathol Clin. 2018 Jun;11(2):403-429. doi: 10.1016/j.path.2018.02.005.
8
Emerging molecular targets and therapy for cholangiocarcinoma.胆管癌的新兴分子靶点与治疗
World J Gastrointest Oncol. 2017 Jul 15;9(7):268-280. doi: 10.4251/wjgo.v9.i7.268.
9
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.胆管癌不同病因亚型的全基因组和表观基因组景观。
Cancer Discov. 2017 Oct;7(10):1116-1135. doi: 10.1158/2159-8290.CD-17-0368. Epub 2017 Jun 30.
10
Epigenome dysregulation in cholangiocarcinoma.胆管癌中的表观基因组失调。
Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1423-1434. doi: 10.1016/j.bbadis.2017.06.014. Epub 2017 Jun 20.